Xeris Biopharma Holdings, Inc. — Form 8-K
Filed July 17, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
Xeris filed an 8-K on July 17, 2026 for period ending July 15, 2026, disclosing Item 3.02 (unregistered sales of equity securities) and Item 8.01 (other events). The filing document does not provide the specific counterparty, dollar amount, share count, or pricing details of the equity transaction—only that it occurred and was reported.
Why this rating
Without disclosed deal size, counterparty, or terms, cannot assess materiality. Routine 8-K filing of likely minor offering; standard disclosure format.
Extracted items
See more from July 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.